6. Smit MAD, Borghaei H, Owonikoko TK, et al. Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC). J Clin Oncol. 2019;37:TPS8577.7. Frederickson RM. A new era of inno...
6. Smit MAD, Borghaei H, Owonikoko TK, et al. Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC). J Clin Oncol. 2019;37:TPS8577. 7. Frederickson RM. A new era of in...
The present invention relates to a bispecific antibody construct comprising a first binding domain that binds to human DLL3 on the surface of a target cell and a second binding domain that binds to human CD3 on the T cell surface. Furthermore, the present invention provides a polynucleotide ...
Recombinant Human DLL3, partial (Active) (CSB-MP882142HU) DLL3 Antibody (ELISA, IHC)(CSB-PA882142LA01HU) Human DLL3 ELISA Kit (CSB-EL006948HU) 参考文献: [1] Giffin, Michael J.,et al. "AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency an...
[16] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.Journal of Clinical Oncology. 2023. 41(16):2893-2903. $再鼎医药(09688)$ #ADC# 其他热门医药报告: ...
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clin Cancer Res 2021;27:1526-37.13. Paz-Ares L, Champiat S...
Here, we review the preclinical and clinical evidence for targeting DLL3 in SCLC and discuss several DLL3-specific therapies being developed for the treatment of SCLC: the antibody-drug conjugate rovalpituzumab tesirine, the bispecific T cell engager immuno-oncology therapy AMG 757, and the ...
a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Epub 2023 Jan 23. PMID: 36689692; PMCID: PMC10414718.[7]Martin Wermke et al., First...
Bispecific antibody constructs binding dll3 and cd3. Google Patents; 2021. Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab Deruxtecan in previously treated HER2-Positive breast Cancer. N Engl J Med. 2020;382:610–21. Article CAS PubMed Google Scholar ...
In addition, tarlatamab (formerly AMG 757), a DLL3-targeting bispecific T-cell engager recently received FDA accelerated approval in May 2024 for the treatment of released small cell lung cancer. In the phase 2 DeLLphi-301 study, tarlatamab showed promising clinical efficacy in patients with ...